Skip to content
About
Our Story
Leadership
Board of Directors
Research Leadership
Development Leadership
Scientific Advisory Board
Bezuclastinib
Our Approach
About Systemic Mastocytosis
About GIST
Our Clinical Trials
Our Expanded Access Policy
Careers
Why Cogent
Our Team
What We Offer
Our Open Roles
Recruiting Scam Alert
Pipelines & Research Targets
Pipeline
Posters & Publications
Patients & Families
Patients & Families
Systemic Mastocytosis (SM)
Gastrointestinal Stromal Tumors (GIST)
Investors & Media
Company Profile
Press Releases
Events
Presentations
Analyst Coverage
Corporate Governance
SEC Filings
Investor Resources
About
Our Story
Leadership
Board of Directors
Research Leadership
Development Leadership
Scientific Advisory Board
Bezuclastinib
Our Approach
About Systemic Mastocytosis
About GIST
Our Clinical Trials
Our Expanded Access Policy
Careers
Why Cogent
Our Team
What We Offer
Our Open Roles
Recruiting Scam Alert
Pipelines & Research Targets
Pipeline
Posters & Publications
Patients & Families
Patients & Families
Systemic Mastocytosis (SM)
Gastrointestinal Stromal Tumors (GIST)
Investors & Media
Company Profile
Press Releases
Events
Presentations
Analyst Coverage
Corporate Governance
SEC Filings
Investor Resources
About
Our Story
Leadership
Board of Directors
Research Leadership
Development Leadership
Scientific Advisory Board
Bezuclastinib
Our Approach
About Systemic Mastocytosis
About GIST
Our Clinical Trials
Our Expanded Access Policy
Careers
Why Cogent
Our Team
What We Offer
Our Open Roles
Recruiting Scam Alert
Pipelines & Research Targets
Pipeline
Posters & Publications
Patients & Families
Patients & Families
Systemic Mastocytosis (SM)
Gastrointestinal Stromal Tumors (GIST)
Investors & Media
Company Profile
Press Releases
Events
Presentations
Analyst Coverage
Corporate Governance
SEC Filings
Investor Resources
About
Our Story
Leadership
Board of Directors
Research Leadership
Development Leadership
Scientific Advisory Board
Bezuclastinib
Our Approach
About Systemic Mastocytosis
About GIST
Our Clinical Trials
Our Expanded Access Policy
Careers
Why Cogent
Our Team
What We Offer
Our Open Roles
Recruiting Scam Alert
Pipelines & Research Targets
Pipeline
Posters & Publications
Patients & Families
Patients & Families
Systemic Mastocytosis (SM)
Gastrointestinal Stromal Tumors (GIST)
Investors & Media
Company Profile
Press Releases
Events
Presentations
Analyst Coverage
Corporate Governance
SEC Filings
Investor Resources
Relationship between KIT inhibition by bezuclastinib and effects on disease burden in mouse models of systemic mastocytosis
American Society of Hematology Annual Meeting
File size: 807.58 KB
Created: December 2025
Updated: December 2025
Hits: 26
Download
Preview
Scroll to Top
